Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
View Patent ↗This invention relates to a novel dosage regimen for administration of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof, namely in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
1. A method for the treatment of AECOPD in a human patient comprising administering to a human patient in need thereof three separate therapeutically effective doses of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof over a period of not longer than ten days with at least one day between every dose.
2. A method of alleviating a symptom of AECOPD in a human patient, comprising administering to a human patient in need thereof three separate therapeutically effective doses of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof over a period of not longer than ten days with at least one day between every dose.
3. A method of increasing the tolerability of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof in a human patient suffering from AECOPD, which comprises administering to a human patient in need thereof three separate doses of a pharmaceutical composition comprising 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof, over a period of not longer than ten days with at least one day between every dose administration.
4. The method of claim 1 , comprising administering three separate doses of a pharmaceutical composition comprising 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof, over a period of not longer than seven days with at least one day between every dose administration.
5. The method of claim 4 , wherein the doses are administered on days 1, 4 and 7.
6. The method of claim 4 , comprising administering three separate doses of a pharmaceutical composition comprising 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof, over a period of five days with at least one day between every dose administration.
7. The method of claim 6 , wherein the doses are administered on days 1, 3 and 5.
8. The method of claim 1 , wherein the doses are administered on days 1, 6 and 10.
9. The method of claim 1 , wherein the amount of the dose of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof is reduced over the course of the three separate administrations.
10. The method of claim 1 , wherein the initial dose of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof is at least 20% greater than either of the subsequent doses.
11. The method of claim 1 , wherein the ratio of the first dose to either the second and/or third dose of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof is in the range of 1:0.8-1:0.2.
12. The method of claim 1 , wherein the therapeutically effective oral dose of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof is in the range of 10 mg-75 mg.
13. The method of claim 12 , wherein a first oral dose of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof is in the range of 35 mg-75 mg.
14. The method of claim 13 , wherein a second oral dose of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof is in the range of 20 mg-40 mg.
15. The method of claim 14 , wherein a third oral dose of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof is in the range of 10 mg-50 mg.
16. A kit comprising three separate therapeutically effective doses of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof and instructions for treating a human patient suffering from AECOPD, said instructions comprising directions to administer said doses separately over a period of not longer than seven days with at least one day between every dose administration.
17. The kit of claim 16 , wherein the doses are administered on days 1, 4 and 7.
18. The kit of claim 16 , wherein the doses are administered on days 1, 3 and 5.
19. A method for the treatment of AECOPD in a human patient, comprising administering to the patient in need thereof not more than three separate therapeutically effective doses of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide, wherein the dose is 25 mg, and wherein the doses are administered on days 1, 6 and 10.
20. A method for the treatment of AECOPD in a human patient, comprising administering to the patient in need thereof not more than three separate therapeutically effective doses of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide, wherein the dose is 75 mg, and wherein the doses are administered on days 1, 6 and 10.